The Life Sciences Report: I know you have great interest in cancer drug development. Do you see hematology/oncology (heme/onc) indications as areas of unmet need right now?
John McCamant: Heme/onc has been an area of success for biotech companies. We have seen Celgene Corp. (CELG:NASDAQ) target multiple myeloma with Revlimid (lenalidomide), and we’ve seen other drugs in this space, such as Genentech/Roche Holding AG’s … [visit site to read more]
